ArticleTranslational lung cancer research2024
Efficacy and safety of consolidative thoracic radiotherapy after first-line chemoimmunotherapy in patients with extensive-stage small-cell lung cancer: a retrospective cohort study.
Article in Translational lung cancer research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Role of thoracic radiotherapy for extensive-stage small cell lung cancer in the era of immunotherapy: a review of current evidence.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Thoracic radiotherapy (TRT) has shown potential benefits in improving local control and overall survival (OS) in chemotherapy-responsive small-cell lung cancer (SCLC) cases. However, its role in the era of chemoimmunotherapy remains underexplored. In the current era of immunotherapy, this study evaluated the efficacy and safety of consolidative TRT (cTRT) in patients with extensive-stage SCLC (ES-SCLC) and assessed its impact on OS. Additionally, the optimal radiotherapy dose and fractionation schemes were also explored. Methods: In this retrospective cohort study, 124 patients with ES-SCLC diagnosed at Taizhou Cancer Hospital between January 2019 and November 2023 were categorized into cTRT and non-cTRT groups. We compared the baseline characteristics, treatment processes, and survival outcomes between the two groups. Moreover, cTRT subgroups of different radiotherapy doses and fractionation schemes were formed and compared in terms of baseline characteristics, radiotherapy efficacy and safety, patterns of recurrence after radiotherapy, and survival outcomes. OS was selected as the primary endpoint for observation. Differences in OS between the groups were analyzed using log-rank tests. Univariable and multivariable Cox regression analyses were performed to identify factors correlated with OS in the overall patient cohort. Results: The baseline characteristics between the two groups (cTRT and non-cTRT) were generally comparable, with the following significant differences: the cTRT group had a lower proportion of females (1.7% Conclusions: cTRT improved the OS of patients with ES-SCLC and exhibited manageable associated toxicity. Further research is needed to confirm the effect of radiotherapy dose and fractionation scheme selection on treatment outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.